Twenty-four months progression-free survival (ongoing) for treatment of recurrent ovarian clear cell carcinoma with surufatinib in combination with toripalimab: a case report.

Recurrent ovarian clear cell carcinoma (OCCC) remains a therapeutic challenge due to intrinsic chemoresistance and paucity of targeted options. Surufatinib is a multi-target tyrosine kinase inhibitor that may enhance antitumor immunity when combined with PD-1 blockade. We report a 53-year-old female with recurrent OCCC who developed a platinum-sensitive first relapse (platinum-free interval, 9.8 months) after adjuvant platinum-based chemotherapy and achieved a 24-month progression-free survival (ongoing) on surufatinib plus toripalimab. The best response was partial response, and treatment was well tolerated except for Grade 1 hemoptysis and Grade 1–2 proteinuria. Radiologic disease control was durable. However, because biomarker assessment relevant to immune checkpoint inhibition was not performed, the biological basis of response remains uncertain. This case suggests the clinical feasibility of surufatinib plus toripalimab and its association with durable disease control in an individual patient with recurrent OCCC. However, given the platinum-sensitive nature of the relapse, treatment efficacy should be interpreted cautiously. Further prospective studies incorporating biomarker assessment are warranted.